|
ACM
|
IF
|
Year
|
特徴 |
| Lancet |
41.5 |
88.5 |
2024 |
|
| N Engl J Med. |
39 |
78.5 |
2024 |
|
| Nat Med. |
30 |
50.0 |
2024 |
|
| Nature |
28
|
48.5
|
2024
|
|
| Science |
23
|
45.8
|
2024
|
|
| Cell |
22 |
42.5 |
2024 |
|
| Ann Oncol. |
19
|
65.4
|
2024
|
|
| Nat Genet. |
19
|
29.0
|
2024
|
|
| Nat. Cancer |
18.5
|
28.5
|
2024
|
|
| Cancer Discov. |
18
|
33.3
|
2024
|
|
| Cell
Metab. |
18 |
30.9 |
2024 |
|
| J Clin Oncol. |
16
|
43.4
|
2024
|
|
| Nat Rev Endocrinol. |
16
|
42.3
|
2024
|
|
| Nat Immunol. |
16
|
27.6
|
2024
|
|
| Nat Biomed Eng. |
16
|
26.7
|
2024
|
|
| Cell Res. |
15
|
44.1
|
2022
|
|
| Circulation |
15
|
37.8
|
2022
|
|
| Immunity |
15
|
26.3
|
2024
|
|
| BMJ |
13
|
43.0
|
2024
|
|
| Mol Cancer. |
13 |
33.9 |
2024 |
|
Sci Immunol.
|
13
|
24.8
|
2022
|
|
| Nat Metab. |
13 |
20.8 |
2024 |
|
Nat Cell Biol.
|
13
|
19.5
|
2024
|
|
| JAMA Intern Med. |
12
|
39.0
|
2022
|
|
| J Hepatol. |
12
|
25.7
|
2022
|
|
| Intensive Care Med. |
11
|
38.9
|
2022
|
|
| JAMA Oncol. |
11
|
20.1
|
2024
|
|
| Sci Transl Med. |
11
|
17.1
|
2022
|
|
| Mol Cell. |
11
|
16.0
|
2022
|
|
| Ann Rheum Dis. |
10
|
27.4
|
2022
|
|
Circ Res.
|
10
|
20.1
|
2022
|
|
| Nat
Commun. |
10
|
15.7
|
2024
|
|
| J Am Chem Soc. |
10
|
15.0
|
2022
|
|
Sci Bull.
|
9
|
18.9
|
2022
|
中国科学院
|
| JACC Cardiovasc Imaging |
9
|
16.051 |
2021
|
|
Ann Intern Med.
|
9
|
15.2
|
2024
|
|
| Clin Cancer Res. |
9
|
13.801
|
2021
|
|
| Sci Adv. |
9
|
13.6
|
2022
|
|
| Dev Cell |
9
|
13.417
|
2021
|
|
| Blood |
8
|
20.3
|
2022
|
|
| Adv Sci. |
8
|
14.1
|
2024
|
|
| J Clin Invest. |
8
|
13.6
|
2024
|
|
| Hepatology |
8
|
13.5
|
2022
|
|
Acta Neuropathol.
|
8
|
12.7
|
2022
|
|
Nat Struct Mol Biol.
|
8
|
10.1
|
2024
|
|
Nature Aging
|
7
|
16.6
|
2022
|
|
| J Exp Med. |
7
|
15.3
|
2022
|
|
J Am Soc Nephrol
|
7
|
14.981
|
2021
|
|
| J Allergy Clin Immunol. |
7
|
14.29
|
2021
|
|
| Autophagy |
7 |
13.3 |
2022
|
|
Neurology
|
7
|
12.258
|
2021
|
|
Mol Ther.
|
7
|
12.4
|
2022
|
|
| Cell Discov. |
7
|
13.0
|
2023
|
|
Genome Biol.
|
7
|
12.3
|
2022
|
|
| EMBO J. |
7
|
11.4
|
2022
|
|
Cancer Res.
|
7
|
11.2
|
2022
|
|
| J Immunother Cancer |
7
|
10.9
|
2022
|
|
Cell Rep Med.
|
7
|
10.6
|
2024
|
|
Am J Hum Genet.
|
7
|
9.8
|
2022
|
|
| Protein Cell |
6
|
21.2
|
2022
|
|
EClinicalMedicine
|
6
|
15.1
|
2022
|
|
| Diabetes Care |
6
|
14.8
|
2023
|
|
| Arthritis Rheumatol. |
6
|
13.3
|
2022
|
|
| Metabolism |
6
|
11.9
|
2024
|
|
Med
|
6
|
11.8
|
2024
|
|
| PLos Med. |
6
|
11.613
|
2021
|
|
| J Nucl Med. |
6
|
11.082
|
2021
|
|
| EBioMedicine |
6
|
9.7
|
2023
|
|
| PLoS Biol. |
6
|
9.593
|
2021
|
|
Aliment Pharmacol Ther.
|
6
|
9.524
|
2021
|
|
| Proc Natl
Acad Sci
U S A. |
6
|
9.1
|
2024
|
|
EMBO Mol Med.
|
6
|
9.0
|
2023
|
|
Genet Med.
|
6
|
8.864
|
2021
|
|
| Oncogene |
6
|
8.756
|
2021
|
|
Am J Clin Nutr.
|
6
|
8.472
|
2021
|
|
| Metab Eng. |
6
|
8.4
|
2022
|
|
Phytomedicine
|
6
|
8.3
|
2024
|
|
| Am J Kidney Dis. |
5
|
11.072
|
2021
|
|
Gastrointest Endosc.
|
5
|
10.396
|
2021
|
|
| Diabetologia |
5
|
10.2
|
2024
|
|
| BMC Med. |
5
|
9.3
|
2022
|
|
| EMBO
Rep. |
5
|
9.071 |
2021
|
|
Cell Chem Biol.
|
5
|
9.039
|
2021
|
|
| Cardiovasc Diabetol. |
5
|
8.5
|
2023
|
|
Eur J Cancer.
|
5
|
8.4
|
2022
|
|
Nanoscale
|
5
|
8.307
|
2021
|
|
| J Cell Biol. |
5
|
8.077 |
2021
|
|
| Cell Death Dis. |
5
|
8.1
|
2023
|
|
Am J Respir Cell Mol Biol.
|
5
|
7.748
|
2021
|
|
Oncoimmunology
|
5
|
7.723
|
2021
|
|
| Antioxid Redox Sign. |
5
|
7.468 |
2021
|
|
Plant Physiol.
|
5
|
7.4
|
2022
|
|
| J Med Chem. |
5
|
7.3
|
2022
|
|
Stem Cell Rep.
|
5
|
7.294
|
2021
|
|
| Aging Cell |
5
|
7.1
|
2024
|
|
| Cell Rep. |
5
|
6.9
|
2024
|
|
| Nucleic Acids Res. |
4
|
16.6
|
2023
|
|
Pediatrics
|
4
|
9.703
|
2021
|
|
Thorax
|
4
|
9.106
|
2021
|
|
Front Immunol.
|
4
|
8.787
|
2021
|
|
Thorax
|
4
|
8.3
|
2024
|
|
| Hypertension |
4 |
8.2 |
2024 |
|
| Antioxidants |
4
|
7.675
|
2021
|
|
| Diabetes |
4
|
7.5
|
2024
|
|
J Transl Med.
|
4
|
7.5
|
2024
|
|
Blood Adv.
|
4
|
6.799
|
2020
|
|
| Sci Signal. |
4
|
6.8
|
2023
|
|
PLoS Pathog.
|
4
|
6.7
|
2022
|
|
| Mol Metab. |
4
|
6.6
|
2024
|
|
| Thyroid |
4
|
6.6
|
2022
|
|
Int J Nanomed.
|
4
|
6.400
|
2020
|
|
| JCI
Insight |
4
|
6.1
|
2024
|
|
| PLoS Genet. |
4
|
6.02 |
2021
|
|
| Mol Cancer Ther. |
4
|
6.011
|
2021
|
|
Stem Cells
|
4
|
5.845
|
2021
|
|
Cancer Immunol Immunother.
|
4
|
5.8
|
2022
|
|
Biochem Pharmacol.
|
4
|
5.8
|
2022
|
|
| Cancer Sci. |
4
|
5.7
|
2022
|
|
Mol Med.
|
4
|
5.7
|
2022
|
|
| J Nutr Biochem. |
4
|
5.6
|
2022
|
|
Genome Res.
|
4
|
5.5
|
2024
|
|
| J Cell Mol Med. |
4
|
5.295
|
2021
|
|
ACS Synth Biol.
|
4
|
5.249
|
2021
|
|
| Hum Mol Genet. |
4 |
5.121 |
2021 |
|
| Commun Biol. |
4
|
5.1
|
2024
|
|
Lab Invest.
|
4
|
5.0
|
2022
|
|
Obesity
|
3
|
6.9
|
2022
|
|
| Atherosclerosis |
3
|
6.847
|
2021
|
|
| Diabetes Obes Metab. |
3
|
6.41
|
2021
|
|
Transl Res.
|
3
|
6.4
|
2023
|
|
Kidney Int Rep.
|
3
|
6.234
|
2021
|
|
Plant Cell Rep.
|
3
|
6.2
|
2022
|
|
Cells
|
3
|
6.0
|
2022
|
|
| Am J Pathol. |
3
|
6.0
|
2022
|
|
Am J Med.
|
3
|
5.928
|
2021
|
|
| Eur J Endocrinol. |
3
|
5.8
|
2022
|
|
| J Neurochem. |
3
|
5.546
|
2021
|
|
| Radiographics |
3
|
5.5
|
2022
|
|
| J Immunol. |
3
|
5.446
|
2021
|
|
Stem Cells Int.
|
3
|
5.443
|
2020
|
|
| J Neurosurg. |
3
|
5.408
|
2021
|
|
| Diabetes Technol Ther. |
3
|
5.4
|
2022
|
|
J Bone Joint Surg Am
|
3
|
5.3
|
2022
|
|
| Mol Cell Biol. |
3
|
5.3
|
2022
|
|
Eur J Pharmacol.
|
3
|
5.195
|
2021
|
|
Antimicrob Agents Chemother.
|
3
|
5.191
|
2020
|
|
Cancer
|
3
|
5.1
|
2024
|
|
| J Bone Miner Res. |
3
|
5.1
|
2023
|
|
| J
Clin Endocrinol Metab. |
3
|
5.1
|
2024
|
editor
reject 50-60% |
Plant Cell Physiol.
|
3
|
4.937
|
2021
|
|
Nutrition
|
3
|
4.893
|
2021
|
|
| Faseb J. |
3
|
4.8
|
2022
|
|
| Nutrients |
3
|
4.8
|
2023
|
|
J Nutr.
|
3
|
4.735
|
2021
|
|
ACS Synth Biol.
|
3
|
4.7
|
2022
|
|
Neurosurgery
|
3
|
4.654
|
2020
|
|
| Development |
3
|
4.6
|
2022
|
|
| Nutr Metab. |
3
|
4.5
|
2022
|
|
Lipids Health Dis.
|
3
|
4.5
|
2022
|
|
Clin Genet.
|
3
|
4.438
|
2020
|
|
J Dairy Sci.
|
3
|
4.4
|
2024
|
|
| J Atheroscler
Thromb. |
3
|
4.394
|
2021
|
日
本動脈硬化学会 |
| Mol Cell Endocrinol. |
3
|
4.369 |
2021
|
|
Surgery
|
3
|
4.348
|
2021
|
|
Chem Eur J.
|
3
|
4.3
|
2022
|
|
| Analyst |
3
|
4.2
|
2022
|
|
Biomed Mater.
|
3
|
4.103
|
2021
|
|
| J Lipid Res. |
3
|
4.1
|
2024
|
|
| iScience |
3
|
4.1
|
2024
|
|
| Endocr-Relat Cancer. |
3
|
4.1
|
2023
|
|
J Cell Sci.
|
3
|
4.000
|
2022
|
|
Phys Chem Chem Phys.
|
3
|
3.945
|
2021
|
|
| Sci Rep. |
3
|
3.9
|
2024
|
審査対象は技術妥当性のみ。リバイス1か月 |
Protein Sci.
|
2
|
6.993
|
2021
|
|
Open Biol.
|
2
|
5.8
|
2022
|
|
| J Endocrinol Invest. |
2
|
5.467 |
2021
|
|
FEBS J.
|
2
|
5.4
|
2022
|
|
Hypertens Res.
|
2
|
5.4
|
2022
|
日本高血圧学会
|
Front Public Health
|
2
|
5.2
|
2022
|
|
| Diabetes Res Clin Pract. |
2
|
5.1
|
2022
|
|
Am J Epidemiol.
|
2
|
5.0
|
2022
|
|
| Clin Chim Acta. |
2
|
5.0
|
2022
|
|
Int J Mol Sci.
|
2
|
4.9
|
2023
|
|
J Hypertens.
|
2
|
4.9
|
2022
|
|
Diabetol Metab Syndr.
|
2
|
4.8
|
2022
|
|
J Epidemiol.
|
2
|
4.7
|
2022
|
|
| Biomedicines |
2
|
4.7 |
2022
|
|
J Diabetes
|
2
|
4.545
|
2021
|
|
| Cancers |
2
|
4.4
|
2024
|
|
Invest Ophthalmol Vis Sci.
|
2
|
4.4
|
2022
|
|
Diabetic Med.
|
2
|
4.359
|
2020
|
|
| J Diabetes Res. |
2
|
4.3
|
2022
|
|
| Biochem J. |
2
|
4.1
|
2022
|
|
| Acta Diabetol. |
2
|
4.087 |
2021
|
|
| Am J Physiol Gastroint Liver
Physiol. |
2
|
3.9
|
2023
|
|
J Clin Med.
|
2
|
3.9
|
2022
|
|
| J Biol Chem. |
2
|
3.9
|
2024
|
査読者はEditorial Board Memberのみ |
| Front
Endocrinol. |
2
|
3.9
|
2023
|
症例報告も可 |
Respiration
|
2
|
3.8
|
2024
|
|
Clin Proteom.
|
2
|
3.8
|
2022
|
|
| BMJ Open Diabetes Res Care. |
2
|
3.7
|
2023
|
|
Front Genet.
|
2
|
3.7
|
2022
|
|
| PLoS One |
2
|
3.7 |
2022
|
審査対象は技術妥当性のみ |
Endocrine
|
2
|
3.7
|
2022
|
|
Biophys J.
|
2
|
3.699
|
2021
|
|
J Biochem Mol Toxicol.
|
2
|
3.642
|
2020
|
|
| Bone |
2 |
3.6 |
2024 |
|
Pharm Biol.
|
2
|
3.503
|
2020
|
|
| FEBS Lett. |
2
|
3.5
|
2022
|
|
| J Mol Endocrinol. |
2
|
3.5
|
2022
|
|
Pituitary
|
2
|
3.4
|
2024
|
|
Mol Biol Cell.
|
2
|
3.3
|
2022
|
|
| Endocrinology |
2
|
3.3
|
2024
|
|
| Life Sci Alliance. |
2
|
3.3
|
2023
|
|
| Adipocyte |
2
|
3.3
|
2022
|
|
J Appl Physiol.
|
2
|
3.3
|
2022
|
|
BMC Endocr Disord.
|
2
|
3.263
|
2021
|
|
| Pancreas |
2
|
3.243 |
2021 |
|
Clin Endocrinol.
|
2
|
3.2
|
2022
|
|
Dev Biol.
|
2
|
3.148
|
2021
|
|
| Am J Physiol Endocrinol Metab. |
2
|
3.1
|
2024
|
|
| J Diabetes Investig. |
2
|
3.1
|
2023
|
アジア糖尿病学会 |
| Prostate Int. |
2
|
3.07
|
2021
|
|
Arch Dermatol Res.
|
2
|
3.017
|
2020
|
|
Clin Nutr ESPEN.
|
2
|
3.0
|
2022
|
|
Anal Biochem.
|
2
|
2.9
|
2022
|
|
Transfusion
|
2
|
2.9
|
2022
|
|
Endocr Connect.
|
2
|
2.9
|
2022
|
|
Neuroendocrinology
|
2
|
2.8
|
2024
|
|
Cognition
|
2
|
2.8
|
2023
|
|
| Steroids |
2
|
2.76
|
2021
|
|
| J Clin Hypertens. |
2
|
2.7
|
2023
|
|
Prostate
|
2
|
2.5
|
2024
|
|
| Biochem Biophys
Res Commun. |
2 |
2.2 |
2024 |
|
Hepatic Med.
|
2
|
2.1
|
2022
|
|
J Obes Metab Syndr.
|
1.5
|
5.2
|
2022
|
|
Metab Open.
|
1.5
|
2.7
|
2024
|
|
Obes Res Clin Pract.
|
1
|
5.214
|
2021
|
|
Expert Opin Drug Saf.
|
1
|
4.011
|
2021
|
|
| J Endocrinol. |
1
|
3.9
|
2024
|
|
| Endocr Pract. |
1
|
3.7
|
2023
|
|
Biol Chem.
|
1
|
3.7
|
2022
|
|
| Diabetes Ther. |
1
|
3.605
|
2021
|
|
Nephron
|
1
|
3.457
|
2021
|
|
J Bronchol Intern Pulmonol.
|
1
|
3.2
|
2024
|
|
Med Princ Pract.
|
1
|
3.2
|
2022
|
|
| J Endocr Soc. |
1
|
3.0
|
2023
|
|
| Horm Metab Res. |
1
|
2.788
|
2021
|
|
Sleep Breath.
|
1
|
2.655
|
2021
|
|
BMC Nephrol.
|
1
|
2.585
|
2021
|
|
Pathol Int.
|
1
|
2.5
|
2023
|
|
| Exp Clin
Endocrinol Diabetes. |
1
|
2.426 |
2021
|
|
Biosci Biotechnol Biochem.
|
1
|
2.337
|
2021
|
|
| Genes Cells |
1
|
2.3
|
2021
|
|
Int Urol Nephrol.
|
1
|
2.266
|
2021
|
|
| Ann Nucl Med. |
1
|
2.258
|
2021
|
|
| World Neurosurg. |
1
|
2.21
|
2021
|
|
Islets
|
1
|
2.2
|
2022
|
|
| Diabetol Int. |
1
|
2.2
|
2022
|
日
本糖尿病学会 |
Thyroid Res.
|
1
|
2.2
|
2022
|
|
| Endocr J. |
1
|
2.1
|
2024
|
日本内分泌学会。症例報告も可。 |
Health Sci Rep.
|
1
|
2.1
|
2024
|
|
BMC Cardiovasc Disord.
|
1
|
2.1
|
2022
|
|
Clin Biomech.
|
1
|
2.034
|
2021
|
|
Urology
|
1
|
2.0
|
2024
|
|
Mol Genet Genom Med.
|
1
|
2.0
|
2022
|
|
J Clin Med Res.
|
1
|
2.0
|
2024
|
症例報告も可能
|
J Child Neurol.
|
1
|
1.9
|
2022
|
|
Ther Apher Dial.
|
1
|
1.762
|
2020
|
|
Vox Sang.
|
1
|
1.6
|
2024
|
|
Protein Expr Purif.
|
1
|
1.6
|
2022
|
|
Semin Dial.
|
1
|
1.6
|
2022
|
|
Bratisl Lek Listy.
|
1
|
1.564
|
2021
|
|
J Pediatr Endocrinol Metab.
|
1
|
1.52
|
2021
|
|
Int Heart J.
|
1
|
1.5
|
2022
|
|
Medicine
|
1
|
1.4
|
2024
|
|
| Intern Med. |
1
|
1.1
|
2024
|
日
本内科学会。症例報告も可 |
Clin Invest Med.
|
0
|
1.279
|
2021
|
|
Clin Lab.
|
0
|
1.053
|
2021
|
|
| Case Reports in Endocrinology |
0
|
0.9
|
2024
|
Wiley社
|
BMJ Case Rep.
|
0
|
0.9
|
2022
|
|
Int J Surg Case Rep.
|
0
|
0.6
|
2022
|
|
| eLife |
|
N/A
|
2024
|
|
J Thyroid Res.
|
-
|
|
2020
|
|
Obes Sci Pract.
|
-
|
|
|
|
JCEM
Case Reports
|
-
|
|
|
|
Endocrinol
Diabetes Metab Case Rep.
|
-
|
|
|
Pubmed(+)。MEDLINE
(-)。Bioscientifica。
|
AACE Clinical Case Reports
|
|
|
|
Pubmed(+)。MEDLINE
(-)。American association of clinical endocrinologist
|
Clin Med Insights Case Rep.
|
|
|
|
Pubmed(+)。MEDLINE(-)。Libertas
Academia
|
Eur J Case Rep Intern Med
|
|
|
|
Pubmed(+)。MEDLINE(-)。SMC Media
|
Int Med Case Rep J.
|
|
|
|
Pubmed(+)。MEDLINE(-)。Dove
Medical Press
|
SAGE Open Med Case Rep
|
|
|
|
Pubmed(+)。MEDLINE(-)。SAGE
Publications
|
World J Clin Cases
|
|
|
|
Pubmed(+)。MEDLINE(-)。Baishideng
Publishing
|
Clin
Case Rep.
|
-
|
|
|
Pubmedにindexされる
|
Cureus
|
-
|
|
2021
|
PubMedにindexされる
|